Research graph
References from Understanding and interpreting composite outcomes in clinical research. Local targets link to admitted publications; unresolved targets remain external evidence.
Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review
10.1186/s12874-021-01440-5 · 2021 · External reference
Combined endpoints: can we use them?
10.1002/sim.1300 · 2002 · External reference
Composite outcome measures in high‐impact critical care randomised controlled trials: a systematic review
10.1186/s13054-024-04967-3 · 2024 · External reference
Unresolved reference
2015 · External reference
Making sense of composite endpoints in clinical research
10.3390/jcm12134371 · 2023 · External reference
Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): a randomized controlled trial
10.1002/jhm.12995 · 2023 · External reference
Impact of pharmacist involvement in the transitional care of high‐risk patients through medication reconciliation, medication education, and postdischarge call‐backs (IPITCH Study)
10.1002/jhm.2493 · 2016 · External reference
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
10.1038/s41591-021-01659-1 · 2022 · External reference
Guidelines for reporting outcomes in trial reports: the CONSORT‐outcomes 2022 extension
10.1001/jama.2022.21022 · 2022 · External reference
The problem with composite end points in cardiovascular studies
10.1016/j.jacc.2007.10.034 · 2008 · External reference
Clinical and safety impact of an inpatient pharmacist‐directed anticoagulation service
10.1002/jhm.910 · 2011 · External reference
Beyond bloodstream infection: the potential for hierarchical composite endpoints in vascular access research
10.1093/cid/ciag276 · 2026 · External reference
Effects of extended‐release metoprolol succinate in patients undergoing non‐cardiac surgery (POISE trial): a randomised controlled trial
10.1016/s0140-6736(08)60601-7 · 2008 · External reference
Composite outcomes in randomized trials: greater precision but with greater uncertainty?
10.1001/jama.289.19.2554 · 2003 · External reference
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
10.1093/eurheartj/ehr352 · 2012 · External reference
Angiotensin‐neprilysin inhibition in heart failure with preserved ejection fraction
10.1056/nejmoa1908655 · 2019 · External reference
Weighted reverse counting process (WRCP): a novel approach to quantify the overall treatment effect with multiple time‐to‐event outcomes by adaptive weighting
2024 · External reference
Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials
10.1016/j.jclinepi.2022.03.009 · 2022 · External reference
Guidelines for reporting outcomes in trial reports: the CONSORT‐outcomes 2022 extension
10.1001/jama.2022.21022 · ExternalCitation · doi-reference
Composite outcomes in randomized trials: greater precision but with greater uncertainty?
10.1001/jama.289.19.2554 · ExternalCitation · doi-reference
Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): a randomized controlled trial
10.1002/jhm.12995 · ExternalCitation · doi-reference
Impact of pharmacist involvement in the transitional care of high‐risk patients through medication reconciliation, medication education, and postdischarge call‐backs (IPITCH Study)
10.1002/jhm.2493 · ExternalCitation · doi-reference
Clinical and safety impact of an inpatient pharmacist‐directed anticoagulation service
10.1002/jhm.910 · ExternalCitation · doi-reference
Combined endpoints: can we use them?
10.1002/sim.1300 · ExternalCitation · doi-reference
The problem with composite end points in cardiovascular studies
10.1016/j.jacc.2007.10.034 · ExternalCitation · doi-reference
Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials
10.1016/j.jclinepi.2022.03.009 · ExternalCitation · doi-reference
Effects of extended‐release metoprolol succinate in patients undergoing non‐cardiac surgery (POISE trial): a randomised controlled trial
10.1016/s0140-6736(08)60601-7 · ExternalCitation · doi-reference
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
10.1038/s41591-021-01659-1 · ExternalCitation · doi-reference
Angiotensin‐neprilysin inhibition in heart failure with preserved ejection fraction
10.1056/nejmoa1908655 · ExternalCitation · doi-reference
Beyond bloodstream infection: the potential for hierarchical composite endpoints in vascular access research
10.1093/cid/ciag276 · ExternalCitation · doi-reference
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
10.1093/eurheartj/ehr352 · ExternalCitation · doi-reference
Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review
10.1186/s12874-021-01440-5 · ExternalCitation · doi-reference
Composite outcome measures in high‐impact critical care randomised controlled trials: a systematic review
10.1186/s13054-024-04967-3 · ExternalCitation · doi-reference
Making sense of composite endpoints in clinical research
10.3390/jcm12134371 · ExternalCitation · doi-reference
